Positive Results for Ebola Vaccine

August 27, 2014
The Pharm Exec staff

Pharmaceutical Executive

Immunovaccine Inc., a clinical stage vaccine company, announced on Aug. 25 positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.

Immunovaccine Inc., a clinical stage vaccine company, announced on Aug. 25 positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.

In a preliminary study, four vaccinated cynomolgus macaque, which are particularly sensitive to the Ebola virus, received two doses of the DepoVax-formulated vaccine before being challenged with a lethal dose of the wild type Zaire strain of the Ebola virus. More than two weeks following exposure to the virus, all vaccinated subjects were alive with no disease symptoms. The two unvaccinated control animals in this study succumbed to the infection within seven days.

This study, conducted under NIAID’s preclinical services program was designed to identify favorable vaccine candidates for further study. Based on this high efficacy observed in cynomolgus macaques, Immunovaccine is exploring a potential development program for an Ebola virus vaccine with various organizations.

Source: Immunovaccine

Related Content:

News